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PAST
Within the field of colorectal cancer (CRC), especially
concerning colorectal liver metastases (CRLM), time to
metastasis is generally seen as an important prognostic
indicator. The interval between resection of the primary
malignancy and the detection of CRLM, also known as the
disease-free interval (DFI), is a key element in the current
clinical risk scores.1,2 A recent analysis questioned this,
when no noticeable prognostic information was found for
the time to metastases in patients with metastatic CRC.3
However, no distinction was made between dissemination
site(s) and local, systemic, or palliative therapy. This study
therefore evaluated the prognostic value of the DFI
specifically in patients with CRLM eligible for surgical
therapy.
PRESENT
Our results indeed show that the prognostic value of the
DFI in patients eligible for surgical treatment of CRLM is
more limited than previously thought.4 The DFI proved
only prognostic for early disease recurrence, but this earlier
disease recurrence did not seem to translate into an
impaired overall survival. While this could be due to a
higher rate of salvage therapy, no correlation was found
between DFI and salvageability for recurrences.
FUTURE
The results of the study show that prognosis prediction
based solely on clinical variables leaves much to be
desired, because the clinical variable assessed only proved
of limited prognostic value. While clinical variables can
sometimes be considered as a proxy for tumor biology,
future efforts to improve prediction modelling should
perhaps be based more on actual biological factors instead.
Potential candidates within the field of CRLM include (but
are not limited to) the histopathological growth patterns
and the quantification of immune infiltration at the tumour
microenvironment.5,6
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